UK Court Ruling A Blow For Pfizer And A Warning For Patentees

A UK Supreme Court decision to invalidate Pfizer's pregabalin patent is not only bad news for Pfizer and good news for the generics firms involved – it could also mean that companies have to produce more evidence to substantiate their patent claims in future.

Patent law
A UK court decision could have major implications for patent claims. • Source: Shutterstock

The UK Supreme Court has invalidated Pfizer’s second medical use patent on Lyrica (pregabalin) in the treatment of neuropathic pain. As well as being a major blow for the Pfizer, lawyers say the ruling could make it more difficult for companies to take out and defend life science patents in future.

“The Supreme Court’s decision is potentially bad news for patentees, not least in the biotechnology and pharmaceutical fields,” said Nick...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet